Ariës Marcel J H, van den Bergh Joop P, Beudel Martijn, Boersma Wim, Dormans Tom, Douma Renee A, Eerens Annet, Elbers Paul W G, Fleuren Lucas M, Gritters van den Oever Niels C, de Haan Lianne, van der Horst Iwan J C C, Hu Shi, Hubers Deborah, Janssen Marcus L F, de Kruif Martijn, Kubben Pieter L, van Kuijk Sander M J, Noordzij Peter G, Ottenhoff Maarten, Piña-Fuentes Dan A I, Potters Wouter V, Reidinga Auke C, Renckens Roos S C, Rigter Sander, Rusch Daisy, Schinkel Michiel, Sigaloff Kim C E, Simsek Suat, Stassen Patricia, Stassen Robert, Thomas Rajat M, van Wingen Guido A, Vonk Noordegraaf Anton, Welling Max, Wiersinga W Joost, Wolvers Marije D J, Wyers Caroline E
Maastricht UMC.
VieCuri Medisch Centrum.
Ned Tijdschr Geneeskd. 2021 Jan 11;165:D5085.
To systematically collect clinical data from patients with a proven COVID-19 infection in the Netherlands.
Data from 2579 patients with COVID-19 admitted to 10 Dutch centers in the period February to July 2020 are described. The clinical data are based on the WHO COVID case record form (CRF) and supplemented with patient characteristics of which recently an association disease severity has been reported.
Survival analyses were performed as primary statistical analysis. These Kaplan-Meier curves for time to (early) death (3 weeks) have been determined for pre-morbid patient characteristics and clinical, radiological and laboratory data at hospital admission.
Total in-hospital mortality after 3 weeks was 22.2% (95% CI: 20.7% - 23.9%), hospital mortality within 21 days was significantly higher for elderly patients (> 70 years; 35, 0% (95% CI: 32.4% - 37.8%) and patients who died during the 21 days and were admitted to the intensive care (36.5% (95% CI: 32.1% - 41.3%)). Apart from that, in this Dutch population we also see a risk of early death in patients with co-morbidities (such as chronic neurological, nephrological and cardiac disorders and hypertension), and in patients with more home medication and / or with increased urea and creatinine levels.
Early death due to a COVID-19 infection in the Netherlands appears to be associated with demographic variables (e.g. age), comorbidity (e.g. cardiovascular disease) but also disease char-acteristics at admission.
系统收集荷兰确诊感染新型冠状病毒肺炎（COVID-19）患者的临床数据。
描述了2020年2月至7月期间在荷兰10个中心收治的2579例COVID-19患者的数据。临床数据基于世界卫生组织COVID病例记录表（CRF），并补充了近期报告的与疾病严重程度相关的患者特征。
进行生存分析作为主要统计分析。已针对病前患者特征以及入院时的临床、放射学和实验室数据确定了至（早期）死亡（3周）时间的这些Kaplan-Meier曲线。
3周后的院内总死亡率为22.2%（95%置信区间：20.7% - 23.9%），老年患者（>70岁；35.0%（95%置信区间：32.4% - 37.8%））以及在21天内死亡且入住重症监护病房的患者（36.5%（95%置信区间：32.1% - 41.3%））在21天内的医院死亡率显著更高。除此之外，在荷兰人群中，我们还发现合并症患者（如慢性神经、肾脏和心脏疾病以及高血压）、使用更多家庭药物和/或尿素及肌酐水平升高的患者存在早期死亡风险。
在荷兰，因COVID-19感染导致的早期死亡似乎与人口统计学变量（如年龄）、合并症（如心血管疾病）以及入院时的疾病特征有关。
